Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Naftifine hydrochloride - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for naftifine hydrochloride and what is the scope of freedom to operate?

Naftifine hydrochloride is the generic ingredient in two branded drugs marketed by Taro Pharms, Tolmar, Sebela Ireland Ltd, and Taro, and is included in eight NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naftifine hydrochloride has three patent family members in three countries.

There are eight drug master file entries for naftifine hydrochloride. Five suppliers are listed for this compound.

Recent Clinical Trials for naftifine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GenZum Life Sciences LLCPhase 3
Semler Research Center Pvt. Ltd.Phase 3
Merz Pharmaceuticals, LLCPhase 4

See all naftifine hydrochloride clinical trials

Recent Litigation for naftifine hydrochloride

Identify potential future generic entrants

District Court Litigation
Case NameDate
Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc.

See all naftifine hydrochloride litigation

Pharmacology for naftifine hydrochloride
Synonyms for naftifine hydrochloride
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethanamine Hydrochloride
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride
(E)-N-CINNAMYL-N-METHYL(1-NAPHTHYLMETHYL)AMINE HYDROCHLORIDE
(E)-N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine- hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-Methyl-N-(3-phenyl-2-propen-1-yl)-1-naphthalenemethanamine Hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, hydrochloride, (E)-
25UR9N9041
65473-14-5
A835130
AB0013289
AB02353
AC-1120
AC1NQY0T
AK326015
AKOS015895211
AN-15212
API0000683
AS-13296
AW 105-843
AW 105843
AW-105-843
AW-105843
BC679571
BCP07446
C-19785
C08072
C1162
CAS-65473-14-5
CCG-213447
CHEBI:7452
CHEMBL1200493
CS-2730
D00883
DSSTox_CID_25496
DSSTox_GSID_45496
DSSTox_RID_80915
DTXSID2045496
Exoderil
H72N880
H827
HMS1571E08
HY-B0518A
I06-0253
J10185
LS-176455
MFCD00059047
MLS002154136
MolPort-003-666-692
N-Methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
N-trans-Cinnamyl-N-methyl-(1-naphthylmethyl)amine Hydrochloride
N-trans-Cinnamyl-N-methyl-(1-napphthylmethyl)amine hydrochloride
NAFT-600
naftifin hydrochloride, (E)-isomer
Naftifine (hydrochloride)
Naftifine HCl
Naftifine Hydrochloride ,(S)
Naftifine hydrochloride (USP)
Naftifine hydrochloride [USAN:USP]
Naftifine hydrochloride [USAN]
Naftifine hydrochloride, 99%
Naftifine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Naftifine, HCl
Naftifungin
Naftin
Naftin (TN)
Naftin hydrochloride
NCGC00016908-01
NCGC00179332-03
NSC-760068
NSC760068
Pharmakon1600-01505446
s3156
SCHEMBL41356
SCHEMBL4932462
SMR001233443
SN 105-843
SN 105843
SN-105843
SR-01000838853
SR-01000838853-2
Suadian
SureCN1649698
Tox21_110677
Tox21_110677_1
UNII-25UR9N9041
Paragraph IV (Patent) Challenges for NAFTIFINE HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
NAFTIN GEL;TOPICAL naftifine hydrochloride 204286 2015-02-04

US Patents and Regulatory Information for naftifine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Tolmar NAFTIFINE HYDROCHLORIDE naftifine hydrochloride CREAM;TOPICAL 206960-001 Apr 10, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for naftifine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKinsey
AstraZeneca
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.